IL257107B - 5-H-T2-C receptor agonists and preparations and methods of use - Google Patents

5-H-T2-C receptor agonists and preparations and methods of use

Info

Publication number
IL257107B
IL257107B IL257107A IL25710718A IL257107B IL 257107 B IL257107 B IL 257107B IL 257107 A IL257107 A IL 257107A IL 25710718 A IL25710718 A IL 25710718A IL 257107 B IL257107 B IL 257107B
Authority
IL
Israel
Prior art keywords
compositions
methods
receptor agonists
ht2c receptor
ht2c
Prior art date
Application number
IL257107A
Other languages
English (en)
Hebrew (he)
Other versions
IL257107A (en
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of IL257107A publication Critical patent/IL257107A/en
Publication of IL257107B publication Critical patent/IL257107B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL257107A 2015-07-31 2018-01-23 5-H-T2-C receptor agonists and preparations and methods of use IL257107B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562199382P 2015-07-31 2015-07-31
PCT/US2016/044426 WO2017023679A1 (en) 2015-07-31 2016-07-28 5-ht2c receptor agonists and compositions and methods of use

Publications (2)

Publication Number Publication Date
IL257107A IL257107A (en) 2018-03-29
IL257107B true IL257107B (en) 2021-03-25

Family

ID=56684262

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257107A IL257107B (en) 2015-07-31 2018-01-23 5-H-T2-C receptor agonists and preparations and methods of use

Country Status (14)

Country Link
US (4) US10272094B2 (cg-RX-API-DMAC7.html)
EP (1) EP3328835B1 (cg-RX-API-DMAC7.html)
JP (1) JP6789578B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180031035A (cg-RX-API-DMAC7.html)
CN (1) CN108137508B (cg-RX-API-DMAC7.html)
AU (1) AU2016302755B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018001707A2 (cg-RX-API-DMAC7.html)
CA (1) CA3002525A1 (cg-RX-API-DMAC7.html)
EA (1) EA039412B1 (cg-RX-API-DMAC7.html)
HK (1) HK1255850A1 (cg-RX-API-DMAC7.html)
IL (1) IL257107B (cg-RX-API-DMAC7.html)
MA (1) MA42527A (cg-RX-API-DMAC7.html)
MX (1) MX375045B (cg-RX-API-DMAC7.html)
WO (1) WO2017023679A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1255850A1 (zh) * 2015-07-31 2019-08-30 Arena Pharmaceuticals, Inc. 5-ht2c受体激动剂和组合物及使用方法
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN110642721B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 盐酸司来吉兰的制备方法
CN110668951B (zh) * 2018-12-21 2022-09-30 安徽贝克生物制药有限公司 一种盐酸司来吉兰的合成工艺
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
WO2023279012A2 (en) * 2021-06-29 2023-01-05 Tusimple, Inc. Systems and methods for operating an autonomous vehicle
US12227206B2 (en) 2021-10-14 2025-02-18 Tusimple, Inc. Systems and methods for operating an autonomous vehicle

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180733A (en) * 1990-03-30 1993-01-19 Abbott Laboratories Biogenic amine uptake inhibitors
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
US6953787B2 (en) * 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
WO2003086303A2 (en) 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
TW200307682A (en) 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
BRPI0411470A (pt) * 2003-06-17 2006-07-11 Arena Pharm Inc derivados de benzazepina úteis para o tratamento de doenças associadas com o receptor de 5ht2c
SI1670768T1 (sl) * 2003-10-08 2010-01-29 Lilly Co Eli Spojine in metode za zdravljenje dislipidemije
US20120253036A1 (en) * 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
JP6198715B2 (ja) * 2012-03-06 2017-09-20 武田薬品工業株式会社 三環性化合物
EP2895485A1 (en) * 2012-09-14 2015-07-22 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
HK1255850A1 (zh) * 2015-07-31 2019-08-30 Arena Pharmaceuticals, Inc. 5-ht2c受体激动剂和组合物及使用方法

Also Published As

Publication number Publication date
EP3328835B1 (en) 2022-10-12
AU2016302755B2 (en) 2020-09-10
US20200383993A1 (en) 2020-12-10
EA201890402A1 (ru) 2018-09-28
NZ739883A (en) 2021-03-26
WO2017023679A1 (en) 2017-02-09
CN108137508A (zh) 2018-06-08
US20230055376A1 (en) 2023-02-23
MA42527A (fr) 2021-04-07
JP6789578B2 (ja) 2020-11-25
MX375045B (es) 2025-03-06
BR112018001707A2 (pt) 2018-09-18
JP2018522025A (ja) 2018-08-09
US11395824B2 (en) 2022-07-26
HK1255850A1 (zh) 2019-08-30
AU2016302755A1 (en) 2018-03-15
MX2018001380A (es) 2018-06-15
US10624900B2 (en) 2020-04-21
US20180214455A1 (en) 2018-08-02
CN108137508B (zh) 2021-08-27
EP3328835A1 (en) 2018-06-06
US10272094B2 (en) 2019-04-30
EA039412B1 (ru) 2022-01-25
CA3002525A1 (en) 2017-02-09
IL257107A (en) 2018-03-29
KR20180031035A (ko) 2018-03-27
US20200078368A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
IL255171A0 (en) 5-Hydroxytryptamine 2-C receptor agonists. and preparations and methods of use
IL274276A (en) CASZ preparations and methods of use
GB2582100B (en) CAS12C Compositions and methods of use
IL259660B (en) Apelin receptor agonists and methods of use
IL257107B (en) 5-H-T2-C receptor agonists and preparations and methods of use
IL264682B (en) 5-HT2C receptor agonists and preparations and methods of use
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
ZA202003664B (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
PT3352766T (pt) Composições de hialuronano de elevada elasticidade e processos para o seu uso
ZA201906169B (en) Synthekine compositions and methods of use
ZA201701909B (en) Trichoderma compositions and methods of use
IL256843B (en) Cleaning products and methods of using them
SG11201803284YA (en) Novel method of use and compositions
IL261794A (en) Preparations and methods for using them
IL254862A0 (en) Preparations for remodeling the intercellular matrix and their use
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
HK40008208A (en) 5-ht2c receptor agonists and compositions and methods of use
PL3548092T3 (pl) Kompozycja rmp i sposoby jej stosowania
GB201720445D0 (en) Use of TRPV1 agonists
ZA201606358B (en) Compositions of selenoorganic compounds and methods and methods of use thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed